Satellos Bioscience Inc.
MSLEHealthcare|Biotechnology|CA
$7.19
+0.84 (+13.23%)
DCF Value
$4.97
Tangible Book / Share
$2.87
Cash / Share
$2.96
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07287189 Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients | Duchenne Muscular Dystrophy, Duchenne | P2 | Active | 51 | RCT, Double-blind | SAT-3247, Placebo |
| NCT07872306 A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral Muscular Dystrophy (FSHD) | P2 | Not Yet Recruiting | 51 | RCT, Double-blind | forazapadin, Placebo Comparator |
| NCT06867107 An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 | Duchenne Muscular Dystrophy (DMD) | P2 | By Invite | 30 | Open-label | SAT-3247 |
| NCT06565208 First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort | Duchenne Muscular Dystrophy | Early P1 | Completed | 77 | RCT, Open-label | SAT-3247, matched placebo |